Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 once-weekly subcutaneous and once-daily oral in type 2 diabetes (dose-finding)
jRCT2031240286Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2024
- Modality
- Small Molecules, Peptides
01
Overview
Phase 2, randomised trial of amycretin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to end of treatment. Started Aug 2024; status: completed.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031240286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240286.